Royal Bank Of Canada Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Neurocrine Biosciences (NASDAQ:NBIX) had its price objective dropped by research analysts at Royal Bank Of Canada from $180.00 to $177.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price objective would suggest a potential upside of 40.64% from the stock’s previous close.

Several other brokerages have also commented on NBIX. BMO Capital Markets cut their target price on Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating on the stock in a research report on Thursday. TD Cowen boosted their price target on Neurocrine Biosciences from $175.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, December 5th. Piper Sandler increased their price target on Neurocrine Biosciences from $175.00 to $179.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. Needham & Company LLC reduced their price objective on shares of Neurocrine Biosciences from $187.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Neurocrine Biosciences in a research report on Thursday, January 22nd. Fifteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $177.50.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock traded down $11.59 on Thursday, hitting $125.85. The company had a trading volume of 1,869,902 shares, compared to its average volume of 1,141,086. Neurocrine Biosciences has a twelve month low of $84.23 and a twelve month high of $160.18. The firm has a market cap of $12.55 billion, a P/E ratio of 30.14, a P/E/G ratio of 0.65 and a beta of 0.31. The stock’s 50-day moving average is $141.39 and its two-hundred day moving average is $140.58.

Insider Buying and Selling

In other news, Director George J. Morrow sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $143.37, for a total value of $2,150,550.00. Following the transaction, the director owned 7,068 shares in the company, valued at $1,013,339.16. This trade represents a 67.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kyle Gano sold 36,400 shares of the company’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $132.70, for a total value of $4,830,280.00. Following the sale, the chief executive officer owned 140,407 shares of the company’s stock, valued at $18,632,008.90. This trade represents a 20.59% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 61,966 shares of company stock valued at $8,625,166. 4.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Loomis Sayles & Co. L P raised its holdings in shares of Neurocrine Biosciences by 5.2% in the 4th quarter. Loomis Sayles & Co. L P now owns 169,220 shares of the company’s stock worth $24,000,000 after purchasing an additional 8,404 shares during the period. Andra AP fonden purchased a new stake in Neurocrine Biosciences in the fourth quarter worth $9,630,000. DJE Kapital AG purchased a new stake in Neurocrine Biosciences in the fourth quarter worth $28,000. Great Lakes Advisors LLC raised its stake in shares of Neurocrine Biosciences by 4.1% in the fourth quarter. Great Lakes Advisors LLC now owns 3,752 shares of the company’s stock valued at $532,000 after buying an additional 147 shares during the period. Finally, Aviva PLC lifted its position in shares of Neurocrine Biosciences by 5.7% during the 4th quarter. Aviva PLC now owns 70,423 shares of the company’s stock valued at $9,988,000 after buying an additional 3,784 shares during the last quarter. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences News Roundup

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Multiple analysts remain constructive—several firms reiterated Buy/Outperform and maintain high price targets (Bank of America reiterated Buy with a $190 target; Needham, HC Wainwright and others also kept Buy ratings), signaling continued Wall Street confidence in the franchise and pipeline. Bank of America reiterates Buy
• Positive Sentiment: Analyst tweaks were modest—Wedbush slightly raised its target and other firms trimmed targets by small amounts while keeping Buy ratings, indicating revisions are more calibration than negative turns. Analyst target movement (Benzinga)
• Neutral Sentiment: Revenue and product sales remained strong: Q4 total revenue roughly $805.5M (+~28% YoY) and full‑year 2025 net product sales ~$2.83B; management gave Ingrezza 2026 net product sales guidance of $2.7–$2.8B. These results support the company’s commercial durability but leave execution and margin questions. PR Newswire: Q4 results & guidance
• Negative Sentiment: EPS missed consensus materially (reported $1.88 vs. Street ~$2.36), which is the primary near‑term catalyst for the selloff—investors reacted to the earnings miss despite revenue growth. MarketBeat: Earnings miss
• Negative Sentiment: Management’s commentary and some analyst notes described cautious 2026 outlook/near‑term cost pressures — that tone, together with the EPS miss, magnified downside pressure. Investing.com: cautious 2026 guidance
• Negative Sentiment: Reported insider selling and some institutional rebalancing were highlighted in aftermarket coverage, which can add mechanical selling pressure on a down day. QuiverQuant: insider selling and stock reaction

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.